Hemophilia A (factor VIII deficiency) is the most common inherited bleeding disorder in the world. The typical clinical manifestation of severe hemophilia is spontaneous joint bleeding. 1 Repeated joint bleeding will lead to irreversible progressive damage of the joint (hemophilic arthropathy). 2 Hemophilia Treatment Center in Jakarta, Indonesia. Hemophilia treatment practice in Indonesia as a developing country is currently improving from the wide use of cryoprecipitate to factor concentrates as episodic treatment but not prophylaxis. Prophylaxis has not become the standard of treatment due to very expensive cost. 3 With episodic treatment, risk of developing hemophilic arthropathy in adulthood is very high and most patients will suffer from chronic pain, 2, 4 physical disability and psychosocial problems in adulthood. 5 To monitor progressivity of hemophilic arthropathy, routine monitoring with clinical and radiological measurement is very important in hemophilia management. 2 International Prophylaxis Study Group (IPSG) has developed Hemophilia Joint Health Score (HJHS), that has good sensitivity and can be applied according to child developmental stage. 6 HJHS evaluates structure and function of bilateral knee, elbow and ankle (total six joints). [6] [7] [8] Currently the best joint imaging to detect early joint damage is magnetic resonance imaging (MRI), but the cost is expensive, not available in every center and needs sedation for children. 9 Ultrasound has been used to assess the joint swelling and differentiate acute bleeding or chronic synovitis without acute bleeding. 10 Martinoli et al 11 developed ultrasound procedure and scoring method named Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) to evaluate knee, elbow, and ankle joint in order to improve sensivity in detecting early sign of arthropathy, using systematical, easy, and fast technique. Joint ultrasound is a potential tool for monitoring hemophilic arthropathy in a developing country as Indonesia, because it is less expensive, widely available, and has a good sensitivity to evaluate soft tissue. 12 The aim of the study was to assess joint health of severe hemophilia A children receiving episodic treatment, in Indonesia National Hemophilia Treatment Center, Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
METHODS
A cross-sectional study was conducted in the Pediatric Hematology-Oncology Division outpatient clinic of Cipto Mangunkusumo Hospital Jakarta as an Indonesian National Hemophilia Treatment Center in MarchSeptember 2015. The protocol of this study has been approved by Medical Ethics Committee of Universitas Indonesia (No. 252/UN2.F1/ ETIK/2015). Written informed consent was obtained from parents of children aged less than 10 years and both parents and child aged >10-18 years. Inclusion criteria were children aged 4-18 years, with severe hemophilia A (factor VIII <1%), history of repeated joint bleeds, and previously received episodic treatment. Exclusion criteria were children with inhibitor factor VIII and/or refusing to participate in the study.
Clinical history
Epidemiological data and clinical history were obtained from the Pediatric Hemophilia Registry and medical record, including age, age of diagnosis, age of first joint bleeding, target joint, number of joint bleedings and factor VIII concentrate received during the last year. Age of diagnosis is the age of the subject when diagnosed as with hemophilia based on factor assay. Age of first joint bleed is the age of the subject when the first joint bleed (one/ more joint/s of the six index joints) occurred. Target joint is defined as a joint in which three or more sponta neous bleeds have occurred within a period of six consecutive months. 2 The number of joint bleedings and factor VIII concentrate usage was collected for the last one year. (minimal/mild-moderate/ severe) and joint damage by looking at the cartilage (normal/cartilage damage <25%/25-50%/>50%/total damage) and the bone (normal/ mild irregularity of subchondral bone with or without osteophytes/deranged subchondral bone with/without erosions and presence of prominent osteophytes around the joint.
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Data analysis
Data analysis was performed using statistical package for social sciences (SPSS) version 20.0. HJHS and HEAD-US scores were analyzed based on two age groups: 4-10 years and >10-18 years. Descriptive analyses for categorical variables were total and percentage, while for numerical variables were mean and standard deviation (normal distributed data) or median and minimum/ maximum range (abnormal distributed data). Unpaired T-test was used to analyze normal data distribution and Mann-Whitney test was used for abnormal distributed data.
RESULTS
During the study period, fifty-nine subjects were enrolled to the study according to inclusion and exclusion criteria. The age of subjects ranged from 6 to 18 years, with mean of 11.7±3.7 years and median of 11.6 years. Twenty-nine out of 59 (49.2%) subjects experienced first joint bleed before two years of age. Thirty-one out of 59 (52.5%) subjects were diagnosed before two years of age. There were 30 out of 59 (50.85%) subjects with target joints, and the most common target joint was right ankle. All subjects had no previous Mean total HJHS and HEAD-US score in subjects with and without target joints are presented in Table 2 . The mean HJHS of subjects aged 4-10 years was 5.7±4.3, with lowest score 0 and highest score 13. In subjects aged >10-18 years, mean HJHS scores was 10.8±9.2 with lowest score 0 and highest score 38. HEAD-US score in subjects aged 4-10 years was 18.7±5.6, lower than in subjects aged >10-18 years (28±7.9, see Table 3 ).
The most affected joints according to HJHS and HEAD-US scores are presented in Figure 1 and Figure 2 . All subjects showed negative inhibitor factor VIII. We present the ultrasonography records of each joint (ankle, knee, and elbow) in Figure 3 .
DISCUSSION
Our study assessed musculoskeletal status using the relatively new measurement tools provided by hemophilia experts: HJHS version 2.1 and There is marked iso-hypoechoic synovial hypertrophy (asterisk) that extending to the cubital fossa. Fluid collection was noted within synovial cavity with internal debris (F). Humeral condyle (HUM) shows irregular surface without cartilage layer. Bony irregularity is also seen at the coronoid process of ulna (ULN); b) Knee sagittal sonography of a 15-years-old male with severe hemophilia (HEAD-US at K1 site). There is only small synovial layer (X) identified at the supra patellar region, without any fluid collection. QF= quadriceps femoris tendon; PF= prefemoral fat pad; PAT= patella; FEM= femur; Posterior ankle sagittal sonography of a 9-years-old male with severe hemophilia (HEAD-US at A3 site). There is marked hypoechoic synovial hypertrophy (yellow arrow) extending posteriorly from talotibial and subtalar joint. TIB= tibia; TAL= talus; CAL= calcaneus; asterisk= Achilles tendon A B C HEAD-US scores. Both measurement have been shown to be reliable with good sensitivity to detect early joint damage, which we consider the most appropriate available tools for our current situation.
Our study showed that 49.2% of subjects had first joint bleeding before the age of 2 years, while 20.3% subjects between 2-5 years. van Dijk et al 1 reported that in 90% of cases with severe hemophilia A, first joint bleeding occurred before the age of 4 years, which is earlier than in mild and moderate hemophilia cases. 1 Pollmann et al reported that 44% of severe hemophilia patients experienced their first joint bleed at the age of ≤1 year, while overall mean age of first joint bleed in the study was 1.9 years. 13 We found that 10 out of 59 (16.9%) subjects had first joint bleed at the age >5 years, this could be due to milder phenotype of severe hemophilia A caused by specific mutations, although factor VIII activity was <1%. Previous studies reported clinical manifestation variability among severe hemophilia A patients. Aledort et al 14 reported that 10-15% of severe hemophilia A patients had milder bleeding phenotype. 14 We found 28 out of 59 (47.4%) subjects had target joints, and 10 of them had more than one target joints. The most common target joint was right ankle (9 out of 43 joints), followed by left ankle and right elbow (both 8 out of 43 joints). Bilateral knees and left elbow were the least target joints. Our data showed that all subjects had multiple joint involvements and the most frequently affected joints were ankles.
HJHS was originally designed to detect early joint damage in patients receiving prophylaxis. However, earlier studies showed that this measurement also applicable for episodically treated patients. 15, 16 Study in Lithuania 16 reported HJHS in 20 hemophilia children receiving episodic treatment, mean total scores in patients aged 4-9 years was significantly lower compare to older children aged 10-17 years (11.6 vs 31.5, respectively). Study in Pakistan 15 on severe (n=59) and non-severe (n=29) hemophilic patients receiving episodic treatment divided into three developmental age groups (<12 years, 12-16 years, and >16 years), the HJHS and Gilbert scores were significantly lower in the youngest group (p<0.001). Our study showed that HJHS and HEAD-US scores in younger age (4-10 years) were significantly lower than in older subjects (>10-18 years), p<0.001; 95% CI=4.913 and p<0.001; 95% CI= -12.9-5.6, respectively). Our study result is similar with data from several studies that showed a strong correlation between age and HJHS. Moreover, in our study, the result of HJHS was supported by ultrasonography scores. Our results supported that HJHS in children receiving episodic treatment demonstrated progressivity of joint damage with increasing age, especially in countries with limited usage of factor concentrates. These results also showed late manifestations of joint impairment in older haemophilia children treated with episodic treatment.
Comparative study in Lithuania-Denmark 17 in patients receiving episodic treatment (n=16) and prophylaxis (n=16) showed better HJHS in prophylaxis group (p<0.001). In the study, subjects Table 3 . HJHS and HEAD-US scores in subjects aged 4-10 years and >10-18 years were stratified according to age (4-9 years and 10-17 years), and the results also showed better HJHS in younger age group receiving prophylaxis treatment; 2.2 vs 12.5 (p=0.0002) and 3.9 vs36.3 (p<0.0001), respectively. The mean difference of HJHS in younger (4-9 years) compare to older (10-17) years children receiving prophylaxis was not significant, 2.2 vs 3.9 (95% CI= -0.4-3.9) respectively. The result supported other clinical trials proving that prophylaxis treatment is superior compare to episodic treatment in preventing joint damage progressivity in children with severe hemophilia. [18] [19] [20] [21] In Indonesia, severe hemophilia chidren receive episodic treatment due to very expensive cost of factor concentrates.
Our study showed that the highest HEAD-US score was found in left ankle in subjects aged 4-10 years, while in subjects aged >10-18 years it was the right ankle. These findings were not corresponding with HJHS results that the most affected joint in subjects aged 4-10 years was left elbow and in subjects aged >10-18 years was right knee. These results may be due to several reasons. Firstly, due to episodic therapy, few subjects may have just recovered from acute hemarthrosis in different intervals prior to HJHS examination that more likely affected HJHS results. We could not wait until two weeks to perform HJHS examination because without prophylaxis we could not predict when the subject will suffer acute hem arthrosis. Secondly, we did not evaluate daily activities between the two agegroups which may affect different target joints.
Our results also showed that HJHS were higher in subjects with target joints (p=0.057; 95% CI=0.0016.9), as well as the HEAD-US scores (p=0.008; 95% CI= -9.8-1.5). These results imply that irreversible joint damage in children treated with episodic therapy is corresponding with joint function evaluated by HJHS. We did not analyze correlation between HJHS and HEAD-US due to insufficient sample size.
Recent observational study reported by Altisent et al 22 showed the utilization of HJHS and HEAD-US scores in severe hemophilia children aged 4-19 years (n=25) treated with prophylaxis treatment and no history of inhibitor. The median of prophylaxis dose was 65.4 IU/kg/week. The annual joint bleeding rate was 0.2, while the median total HJHS was 0 (range 0-13) and total HEAD-US 1 (0-8). Ultrasound examination detected minimal changes in 19.6% of joints with normal physical function, on the contrary 12.2% of joints with normal ultrasound results showed changes in HJHS results. The authors concluded that ultrasonography with HEAD-US method detected a higher percentage of abnormalities than the physical evaluation, however clinical implications of these findings still need to be determined in larger prospective cohort. In the study, total HJHS scores correlated with age (r=0.56, p=0.006), weight (r=0.61, p=0.002), and age at the start of prophylaxis (r=0.63; p=0.001). 22 In our study, the HJHS and HEAD-US scores were higher compared to Altisent's study 22 due to different treatment regimen, showing that prophylaxis can preserve joint function and prevent joint damage in children with severe hemophilia A.
Our study has several limitations. This was the first time HJHS and HEAD-US procedures were applied to assess joint status in our hospital. HJHS has demonstrated good construct validity and internal validity, but has not been used as routine evaluation in our center. The HEAD-US is a novel ultrasound technique that needs to be validated in large series of patients. There is also a possibility of different daily activity among subjects that we did not evaluate. Retrospective data of number of joint bleedings and factor VIII used for episodic treatment in our study together with a cross-sectional evaluation of joint status needs to be confirmed with prospective studies.
In conclusion, we found that joint outcome of severe hemophilia A children receiving episodic treatment in our center evaluated by HJHS and ultrasonography showed more severe damage in older (aged >10-18 years) compare to younger (aged 4-10 years) children. It is important to perform routine evaluation of joint status to monitor progressivity of joint damage over time, so treatment adjustment can be considered. Episodic treatment has been proven to show poor joint outcome in children with severe hemophilia, however there are barriers for implementing prophylaxis treatment in developing countries as Indonesia .
